ConductScience.org, home
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis
API referenceFor AI assistants

Trial · NCT03398148

Results by group97

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 97

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Sub-Study 1: Percentage of Participants Achieving Clinical Remission Per Adapted Mayo ScoreSubstudy 1, Induction Period 1: Double-blind Placebo IV1Participants
Sub-Study 1: Percentage of Participants Achieving Clinical Remission Per Adapted Mayo ScoreSubstudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV7Participants
Sub-Study 1: Percentage of Participants Achieving Clinical Remission Per Adapted Mayo ScoreSubstudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV6Participants
Sub-Study 1: Percentage of Participants Achieving Clinical Remission Per Adapted Mayo ScoreSubstudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV6Participants
Sub-Study 1: Percentage of Participants Achieving Clinical Remission Per Adapted Mayo ScoreSubstudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV42Participants
Sub-Study 2: Percentage of Participants Achieving Clinical Remission Per Adapted Mayo ScoreSubstudy 2, Induction Period 1: Double-blind Placebo IV6.295% Confidence Interval 3.6 to 8.9percentage of participants
Sub-Study 2: Percentage of Participants Achieving Clinical Remission Per Adapted Mayo ScoreSubstudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV20.395% Confidence Interval 17.2 to 23.4percentage of participants
Sub-Study 1: Percentage of Participants Achieving Endoscopic ImprovementSubstudy 1, Induction Period 1: Double-blind Placebo IV3Participants
Sub-Study 1: Percentage of Participants Achieving Endoscopic ImprovementSubstudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV15Participants
Sub-Study 1: Percentage of Participants Achieving Endoscopic ImprovementSubstudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV8Participants
Sub-Study 1: Percentage of Participants Achieving Endoscopic ImprovementSubstudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV9Participants
Sub-Study 1: Percentage of Participants Achieving Endoscopic ImprovementSubstudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV61Participants
Sub-Study 1: Percentage of Participants Achieving Clinical Response Per Adapted Mayo ScoreSubstudy 1, Induction Period 1: Double-blind Placebo IV12Participants
Sub-Study 1: Percentage of Participants Achieving Clinical Response Per Adapted Mayo ScoreSubstudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV26Participants
Sub-Study 1: Percentage of Participants Achieving Clinical Response Per Adapted Mayo ScoreSubstudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV28Participants
Sub-Study 1: Percentage of Participants Achieving Clinical Response Per Adapted Mayo ScoreSubstudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV31Participants
Sub-Study 1: Percentage of Participants Achieving Clinical Response Per Adapted Mayo ScoreSubstudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV157Participants
Sub-Study 1: Percentage of Participants Achieving Clinical Response Per Partial Adapted Mayo ScoreSubstudy 1, Induction Period 1: Double-blind Placebo IV15Participants
Sub-Study 1: Percentage of Participants Achieving Clinical Response Per Partial Adapted Mayo ScoreSubstudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV20Participants
Sub-Study 1: Percentage of Participants Achieving Clinical Response Per Partial Adapted Mayo ScoreSubstudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV28Participants

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03398148/results

API referenceFor AI assistants